Treatment with any other investigational agent within 4 weeks (or within five half-lives of the investigational product, whichever is shorter) prior to cycle 1, day 1 (minimum of 1 week between prior therapy and study enrollment); patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an “early phase I study” or “pre-phase I study” where a sub-therapeutic dose of drug is administered) at the coordinating center PI’s discretion, and should have recovered to eligibility levels from any toxicities
No treatment with any other type of investigational agent =< 4 weeks before pre-registration
Treatment with any other investigational agent within 4 weeks prior to randomization
Participants who are currently receiving any other investigational agents; treatment with an investigational agent within 2 weeks prior to planned initiation of study therapy is allowed provided that any drug-related toxicity has completely resolved
Treatment with another investigational agent under the following conditions:
Concomitant treatment with another investigational agent while participating this trial.
-  Treatment with an immunomodulatory agent within 4 weeks prior to first administration of BI 836858.
Previous treatment with any other investigational agent in the 4 weeks prior to study drug administration (Cycle 1 Day 1)
Investigational treatment - 4 weeks
Treatment with an investigational agent within 4 weeks of the first dose of treatment
SAFETY RUN-IN: Patients participating in another trial of an investigational agent within 4 weeks of the first dose of the study
Exposure to any other investigational agent at any time within 4 weeks before the first dose of study treatment
Treatment with any investigational agent within 4 weeks prior to baseline
Prior investigational therapy (medications or devices) within 6 weeks of treatment.
Subjects on treatment with chemotherapy or any investigational therapeutic agent will need to discontinue therapy 4 weeks prior to registration (wash out period)
Prior systemic anti-cancer therapy including investigational agent within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent
Other investigational therapy: at least two weeks since any other investigational therapy
Treatment with an investigational agent within 4 weeks of registration
Plans to initiate treatment with an investigational agent during the study
Treatment with any investigational agent within 14 days of first administration of study treatment is not permitted
Subjects who anticipate use of other investigational or non-investigational agents for the treatment of MDS during the study period, aside from a stable dose of erythropoietin stimulating agent started >8 weeks prior to screening for this study.
Treatment with any investigational agent within 28 days of first administration of study treatment.
Administration of any investigational agent within 4 weeks prior to initiating study treatment
Patients participating in another trial of an investigational agent within 4 weeks of the 1st dose of the study
Subject has received an investigational therapeutic agent for prostate cancer within 4 weeks prior to the administration of 131I-MIP-1095
An interval of >= 4 weeks after the last administration of any investigational agent or any other treatment prior to first dose of pembrolizumab
Administration of any investigational agent within 4 weeks prior to initiating study treatment
Concurrent treatment with any other investigational agent
Is currently participating in a study of an investigational agent and received an investigational agent within 4 weeks of the first dose of treatment
Treatment with any other investigational agent within 3 weeks prior to the first dose of MEDI4736 and tremelimumab
Any investigational agent within 4 weeks prior to initiating study treatment
Receipt of a prior investigational study agent within 4 weeks prior to enrollment; *Note- patients who have received anti-CD19 CART cells (e.g. CART19/cytotoxic T lymphocyte [CTL] 019) on an investigational study where cell infusion occurred greater than 4 weeks before the screening visit are NOT excluded
Received investigational treatment in another clinical study within 4 weeks prior to the initiation of investigational treatment;
Major surgery or treatment with any other investigational agent within 4 weeks
Any investigational agent within 4 weeks prior to initiating study treatment
Any investigational agent within 4 weeks of study treatment initiation
Patients may not receive concurrent treatment with other investigational or commercial agent(s) for treatment of their breast cancer
Use of any investigational agent within 4 weeks prior to study entry.
Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past 2 weeks prior to initiation of treatment with study drugs
Treatment with an investigational anti-cancer agent within 4 weeks prior to enrollment into the study
Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past 2 weeks prior to initiation of treatment with study drugs
Research participant must be at least 2 weeks out from having received the last dose of investigational agent
Use of any investigational agent within 4 weeks prior to the Baseline Visit.
Patients should not have received an investigational agent for at least 2 weeks prior to the first study drug dose
Investigational agent within 4 weeks of first dose of study treatment
Patients may not have used any investigational agent within 4 weeks prior to enrollment into the study
While on this study, patients may not be treated with any other investigational agent for any purpose until relapse or progression
Treated with any investigational therapy within 2 weeks of the first dose of study treatment.
Administration of any unlicensed or investigational agent within 4 weeks of entry to the study
No prior investigational agent in the 4 weeks prior to initiation of therapy
Use of any investigational agent within 4 weeks prior to study entry.
4 weeks from any investigational agent
Exposure to any investigational agent within 4 weeks prior to initiation of study treatment.
Less than 4 weeks since use of another investigational agent
Treatment with any investigational agent within 4 weeks prior to baseline
Treatment with any investigational agent within 4 weeks prior baseline
Patients who have received treatment with any other investigational agent within 4 weeks before initiation of study treatment
Any antineoplastic agent for the primary malignancy (standard or investigational) without delayed toxicity within 4 weeks prior to first administration of IMP and during study with exceptions
Treatment with any other investigational anti-leukemia agent
Non-nitrosourea cytotoxic drug or any systemic investigational agent with exception of methotrexate ? 4 weeks
Any investigational agent(s) within 4 weeks prior to entry
Treatment with any other investigational agent or investigational device within 4 weeks prior to registration (or within five half-lives of the investigational product, whichever is longer); patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an “early phase I study” or “pre phase I study” where a sub- therapeutic dose of drug is administered) at the coordinating center principal investigator (PI)’s discretion, and should have recovered to eligibility levels from any toxicities
Treatment with other investigational agent within 4 weeks to the first dose of tremelimumab or durvalumab
Investigational therapy within 3 weeks.
Concurrent administration of any other investigational agent considered to have potential efficacy in the treatment of breast cancer
Any investigational agent within 4 weeks prior to initiating study treatment
Ongoing treatment with any other cancer therapy or investigational agent, with the exception of intrathecal (IT) chemotherapy for leukemia, when indicated
Concurrent treatment with an investigational agent
An interval of >= 4 weeks after the last administration of any investigational agent, bevacizumab, or prior cytotoxic therapy
Subjects having received any other investigational agents within 4 weeks prior to the\n             first study drug administration and have not recovered completely (to AEs <  Grade 2)\n             from the side effects of the earlier investigational agent
Treatment with any investigational agent within two weeks prior to first dose in this study; hydroxyurea is allowed to control the AML prior to treatment on the study
Patients with a history of prior therapy with another investigational agent within 4 weeks of the first planned dose of PF-0444913
Concurrent treatment with an investigational agent other than the investigational agent(s) used in this study OR treatment within 4 weeks of study entry with any investigational agent(s) or device(s)
Prior chemotherapy (except PLD in Dose Escalation Cohorts only) or any investigational agent within 3 weeks prior to registration
Any intravesicular or other chemotherapy treatment within 2 weeks or any investigational agent within 4 weeks prior to the initial dose of study drug.
Any investigational agent within 3 weeks of Day 1 of trial drug treatment
First day of dosing with tesevatinib is less than 2 weeks from treatment with another investigational agent
Patients who have received treatment with any other investigational agent within 4 weeks before enrollment.
No investigational agent within 4 weeks prior to first dose of study drug.
Have been treated with an investigational agent within 4 weeks prior to the first day of IP administration.
Treatment with radiotherapy, any chemotherapeutic agent, systemic steroids used as an anti-neoplastic agent, or any other investigational anti-cancer agent within 2 weeks prior to Cycle 1, Day 1
Treatment with any other investigational agent
Treatment with an investigational agent within 4 weeks of starting treatment.
Treatment with any systemic anticancer treatment or an investigational agent within 4 weeks and any radiation within 2 weeks of registration
Treatment with any investigational agent within three weeks prior to first dose in this study
Treatment with any investigational agent within 28 days of first administration of study treatment
Treatment with any investigational agent within three weeks prior to first dose in this study
Taking an investigational agent within 4 weeks of initiation of everolimus
Administration of an investigational agent within 4 weeks of Treatment Cycle 1, Day 1
At least 4 weeks must have elapsed from the use of any other investigational agent prior to starting study drug
Treatment with investigational therapy within 2 weeks of study treatment
If a subject previously received investigational treatment, the last dose of investigational treatment was administered within 4 weeks of Day 1 of the study or adverse event(s) attributable to investigational treatment have not resolved to Grade 1 or better.
Use of any investigational agent within 4 weeks prior to study entry.
Patients who have participated in a window study (treatment with an investigational agent prior to surgery for =< 2 weeks) are eligible; patients must have discontinued the investigational agent at least 14 days before participation
Treatment with an investigational agent within 4 weeks before dosing
Treatment with any investigational agent within 14 days of first administration of study treatment
Ongoing treatment with any other investigational therapy
Treatment with chemotherapy, radiotherapy, surgery, blood products, or an investigational agent within 3 weeks of trial enrolment
No use of an investigational agent within 2 weeks of starting ECP
Current active treatment with an investigational agent
complete abstinence from intercourse from 2 weeks prior to administration of the 1st dose of study agent and 6 months after the last dose of study agent; or
Any investigational agent within 4 weeks of first dose of study treatment
Any investigational agent, other than NEOD001, within 4 weeks
Ongoing investigational treatment
Use of an investigational agent within 4 weeks of Day 1 visit.
Other investigational agent within 3 weeks prior to initiation of study therapy
Concurrent treatment or treatment within 4 weeks of study entry with any other investigational agent or chemotherapy.
Concurrent treatment or treatment within 4 weeks of study entry with any other investigational agent or chemotherapy.
Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past 2 weeks prior to initiation of treatment with study drugs
Receipt of any investigational agent within 4 weeks prior to 1st dose
Treatment with any investigational agent within 3 weeks prior to first dose in this study.
Treatment with another investigational agent under the following conditions:
Concomitant treatment with another investigational agent while participating in this trial.
Current treatment with another investigational agent.
More than 4 weeks from any investigational agent.
Ongoing treatment with any other investigational therapy
Concurrent treatment with an investigational agent
Treatment with any investigational agent <=3 weeks prior to first dose of study treatment
Prior treatment with an investigational or approved agent for the purpose of inhibiting HER family members
Patients may not have received an investigational agent within 4 weeks of starting this trial
Any antineoplastic agent (standard or investigational) within 2 weeks prior to starting trial treatment
Received an antineoplastic therapy or investigational agent after treatment with talazoparib in the originating protocol.
Patient is using or plans to use an investigational agent for the prevention or treatment of VOD.
Concurrent treatment with other investigational agent
Treatment with any local or systemic anti-neoplastic therapy or any other investigational agent in the 4 weeks prior to study drug administration
2 weeks since any oral anti-neoplastic or oral investigational agent
use of any investigational drug within 4 weeks of dosing (unless a longer time period is required by local regulations or the investigational agent)
Patients who have been treated with chemotherapy, with biological therapy or other investigational agent must have discontinued the treatment at least 2 weeks (14 days) prior to starting the study drug on Study Day -
No investigational agent within 4 weeks prior to first dose of study drug
